blue and white gradient background
blue and white gradient background
blue and white gradient background

Step Forward
Personalize treatment decisions for RA patients

PrismRA® is a first-of-its kind molecular signature test that gives providers objective insights to drive RA treatment decisions.

The blood test analyzes each patient’s unique molecular signature, predicting if a patient is well suited for TNF inhibitor (TNFi) therapies such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab with 90% accuracy.1

Now, providers can help improve their patients’ outcomes by identifying those unlikely to respond adequately to TNFi therapies prior to treatment initiation and directing them to a more appropriate therapy sooner.

Learn how PrismRA was developed
prism network

Results you can act on

PrismRA predicts a patient’s likelihood of non-response to TNFi therapies.

NO SIGNAL

Molecular signal of non-response not detected

MODERATE

likelihood of non-response

HIGH

likelihood of non-response

VERY HIGH

likelihood of non-response

Likelihood of TNFi response

More Likely Less Likely

PrismRA can be easily incorporated into your practice